NTRK3 and olfactory neuroblastoma: Patient 27 (esthesioneuroblastoma with NTRK3 amplification) who was treated with the TKI crizotinib developed an altered taste, weight loss, nausea, color perception disturbances, swelling of the right lower leg of unclear etiology, liver enzyme elevations and neutropenia (CTCAE grade 2–3).